← Back to Search

Brachytherapy

High dose rate prostate brachytherapy for Prostate Cancer (BrachyTRACKS Trial)

Q: Is the recruitment phase for this medical study currently ongoing?

<p>According to the latest update on clinicaltrials.gov, this study is no longer actively seeking participants. The trial was first listed on February 1st, 2024 and last modified on December 29th, 2023. However, it's worth noting that there are currently 1217 other studies actively recruiting participants at this time.</p>

N/A

Recruiting

Led By Juanita M Crook, MD

Research Sponsored by British Columbia Cancer Agency

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Selected intermediate risk patients not defined above: T1c/T2a, PSA < 10 and Gleason 4+3, PSA > 10 and Gleason 3+4, PSA 10-15 ng/ml and Gleason 4+3 and < 33% cores involved, Max tumor length in any core 10 mm, No androgen deprivation therapy (ADT), Signed study specific informed consent

Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1-2 weeks, psa: 0-10 years

Awards & highlights

BrachyTRACKS Trial Summary

This trial is studying the effectiveness of a type of radiation treatment called HDR brachytherapy for localized prostate cancer. The study will use different types of tests to understand how this treatment works and how it

Who is the study for?

This trial is for individuals with localized prostate cancer who are suitable candidates for a type of radiation therapy called High Dose Rate (HDR) brachytherapy. Specific eligibility details aren't provided, but typically participants would need to meet certain health standards and not have advanced or metastatic disease.Check my eligibility

What is being tested?

The study is testing HDR brachytherapy as a solo treatment for prostate cancer. It aims to understand how this therapy works by analyzing changes in tumor chemistry, immune response, gene expression, and other biological processes after treatment.See study design

What are the potential side effects?

While specific side effects are not listed here, HDR brachytherapy can generally cause urinary symptoms like discomfort or frequency, bowel issues such as diarrhea or rectal soreness, erectile dysfunction, and fatigue.

BrachyTRACKS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My prostate cancer is not high-risk and I am expected to live 10 more years.

Select...

I am fully active or can carry out light work.

Select...

My prostate cancer is at an intermediate risk level, with specific PSA and Gleason scores.

Select...

My prostate cancer is at an early stage, with specific PSA and Gleason scores.

Select...

My prostate cancer is in an early stage, with low PSA and Gleason scores.

BrachyTRACKS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1-2 weeks, psa: 0-10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1-2 weeks, psa: 0-10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-2 weeks, psa: 0-10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in biomolecular composition in prostate cancer after high dose rate prostate brachytherapy as measured by Raman spectroscopy

Gut microbiome

Immunogenicity against somatic mutations

+1 more

Secondary outcome measures

Acute and long term toxicity

Response Outcome: 4-year PSA

Response Outcome: PSA Nadir

BrachyTRACKS Trial Design

1Treatment groups

Experimental Treatment

Group I: High dose rate prostate brachytherapyExperimental Treatment1 Intervention

Radiation. High dose rate prostate brachytherapy is delivered under anesthesia in 2 procedures, 1-2 weeks apart. HDR brachytherapy is also accomplished as an out-patient.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor

171 Previous Clinical Trials

90,411 Total Patients Enrolled

24 Trials studying Prostate Cancer

5,812 Patients Enrolled for Prostate Cancer

Vancouver Prostate CentreOTHER

9 Previous Clinical Trials

775 Total Patients Enrolled

6 Trials studying Prostate Cancer

393 Patients Enrolled for Prostate Cancer

University of British ColumbiaOTHER

1,418 Previous Clinical Trials

2,467,018 Total Patients Enrolled

11 Trials studying Prostate Cancer

3,139 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment phase for this medical study currently ongoing?

"According to the latest update on clinicaltrials.gov, this study is no longer actively seeking participants. The trial was first listed on February 1st, 2024 and last modified on December 29th, 2023. However, it's worth noting that there are currently 1217 other studies actively recruiting participants at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

Juanita Crook 2024. "Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06200974.